Welcome to our dedicated page for SciSparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.